JSKN-003

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameJSKN-003
Drug Alias NameJSKN-003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-HER2DNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursFallopian Tube Diseases +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAlphamab Oncology
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAlphamab OncologyAlphamab (Australia) Co Pty LtdShanghai Jmt-Bio Inc +[4] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursFallopian Tube Diseases +[12] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A